afami-cel
adaptimmune
['afami-cel', 'sarcoma', 'pivotal', 'adaptimmune']
today at #asco22 at 8 am edt, from will present pooled data of patients with synovial #sarcoma and mrcls treated with afami-cel in the pivotal spearhead-1 and phase 1 trials. click below to see the poster. #cancer #immunotherapy
Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment